China Diabetes Devices Market Size
|Study Period:||2018 - 2028|
|CAGR:||> 4 %|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and it's growth?
China Diabetes Devices Market Analysis
The China Diabetes Devices Market is expected to register a CAGR greater than 4% over the forecast period, 2022-2027.
According to WHO in January 2020 COVID -19 deaths, there are 20% of people with diabetes and diabetes-related diseases happened in China. Nearly one in ten COVID-19 patients have diabetes in China. Diabetes is associated with a higher risk of severe illness and death. The present study suggested that targeted early intervention is needed in COVID-19 patients with diabetes. According to a study conducted by Peking University, (Beijing China) the intensive care unit (ICU) cases had a roughly three-fold greater frequency of diabetes than non-ICU individuals. Various research produced different findings about the prevalence of diabetes. Almost 60% of those with diabetes experienced food or medication shortages during the quarantine period, which was much higher than those without diabetes. Importantly, respondents who experienced medication shortages reported a 63% higher COVID-19 infection rate.
In 2021, Type 1 diabetes patients accounted for 9.84% of the total diabetes population in China. In China, due to lifestyle and food habits, blood glucose fluctuations among insulin users are frequent from time to time, and self-monitoring of blood glucose fails to accurately reflect the blood glucose profile because it only represents the glucose concentration at a specific time point. Thus, a trend has been observed in the demand for the Diabetes Devices in China.
China Diabetes Devices Industry Segmentation
China Diabetes Devices Market is expected to register a CAGR greater than 4% over the forecast period, 2022-2027. China Diabetes Devices Market is segmented into Management Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, Jet Injectors), and Monitoring Devices (Self-monitoring Blood Glucose, Continuous Glucose Monitoring). The report offers the value (in USD million) for the above segments.
China Diabetes Devices Market Trends
This section covers the major market trends shaping the China Diabetes Devices Market according to our research experts:
Monitoring Devices Market is growing with the highest CAGR
Patients with type 1 diabetes (T1D) must maintain healthy lifestyle conditions, which are impacted by the combination of a person's personality traits, social interactions, socioeconomic circumstances, and environmental living factors. The use of continuous glucose monitoring (CGM) with multiple daily injections (MDI) has shown a reduction in nonsevere and severe hypoglycemia in people with T1D prone to this adverse event. Patients with T1D who are at a high risk of hypoglycemia may control their blood sugar levels even amid the harsh living circumstances imposed by the COVID-19 pandemic crisis' severe lockdown thanks to the use of standalone continuous glucose monitoring. A little improvement in glucometric markers, particularly those connected to glucose exposure, was linked to the lockdown time. The Spanish hospitals are ordering CGM devices to limit staff contact with a large portion of diabetic patients infected with COVID-19.
Treatment for viral infections in diabetic people might be challenging because of BG level variations. With RT-CGM, it is possible to monitor BG trends and stop drastic fluctuations in glucose levels before they cause problems. The Dexcom G4 Platinum CGM system's ability to monitor from up to 6.0 m reduced the requirement for medical personnel to enter the isolation room. These factors driving the Monitoring Devices Market in China.
To understand key trends, Download Sample Report
Increasing Type -1 Diabetes Population in China
According to estimates, 1 in 10 Chinese citizens in the country have diabetes. During the 21st Century, millions of new cases of diabetes are occurring each year However, a precise statistic for diabetes in China is difficult to calculate because many cases are considered to remain undetected. China is considered to have surpassed India as the country with the greatest diabetes population in the world. Diabetes is most prevalent in China's cities, where economic growth is accelerating and traditional dietary patterns are rapidly eroding. According to China health experts, the key causes of this diabetes number spike include urbanization, improving living standards, and an aging population. According to the National Health Commission, China has made steps to reduce diabetic and high blood pressure patients' medical expenses by reimbursing outpatients for more than half of their medication costs (NHC). According to a national metabolic disease clinical research center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment. According to the National Health Commission, China Statistics, MMCs across the country have provided services for more than 200,000 patients over the last two years.
As a result, the diabetes care market in China is predicted to expand gradually in the coming years.
China Diabetes Devices Industry Overview
The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.
China Diabetes Devices Market Leaders
Becton, Dickinson & Company
*Disclaimer: Major Players sorted in no particular order
China Diabetes Devices Market News
- In May 2021, Chinese medical device innovation hub Dinova Medtech and US-based medical device company Metronom Health established a joint venture to develop and sell a continuous glucose monitoring system in China. Metronom sees its "disruptive" technology pushing the advancement of digital diabetes management, providing patients with diabetes-related education, data analysis, and other services.
- In May 2021, Bobang Fangzhou announced that the home version of the non-invasive blood glucose meter has been launched on the market and will increase its market launch, focusing on offline sales, and will expand online in the future channel. In the future, Bobang Fangzhou will continue to add clinical data to improve algorithms and explore non-invasive continuous blood glucose testing.
China Diabetes Devices Market Report - Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 Industry Attractiveness - Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Device
5.1.1 By Monitoring Devices, (Value and Volume, 2016-2027)
188.8.131.52 Self-monitoring Blood Glucose Devices
184.108.40.206.1 Glucometer Devices
220.127.116.11.2 Test Strips
18.104.22.168 Continuous Glucose Monitoring
22.214.171.124.2 Receivers (Receivers and Transmitters)
5.1.2 By Management Devices, (Value and Volume, 2016 - 2027)
126.96.36.199 Insulin Delivery Devices
188.8.131.52.1 Insulin Pump
184.108.40.206.1.1 Insulin Pump Device
220.127.116.11.1.2 Insulin Pump Reservoir
18.104.22.168.1.3 Infusion Set
22.214.171.124.2 Insulin Syringes
126.96.36.199.3 Insulin Disposable Pens
188.8.131.52.4 Insulin Cartridges in Reusable pens
184.108.40.206.5 Insulin Jet Injectors
6. MARKET INDICATORS
6.1 Type 1 Diabetes Population (2016 - 2027)
6.2 Type 2 Diabetes Population (2016 - 2027)
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.3 Johnson & Johnson
7.1.4 Novo Nordisk
7.1.5 Becton, Dickinson & Company
7.1.9 ARKRAY Inc.
7.1.10 Ascensia Diabetes Care
7.1.11 ACON Laboratories Inc.
7.1.12 Eli Lilly
7.1.13 Bionime Corporation
7.1.14 Rossmax International Ltd
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
China Diabetes Devices Market Research FAQs
What is the study period of this market?
The China Diabetes Devices Market is studied from 2018 - 2028.
What is the growth rate of China Diabetes Devices Market?
The China Diabetes Devices Market is growing at a CAGR of >4% over the next 5 years.
What is China Diabetes Devices Market size in 2018?
The China Diabetes Devices Market is valued at 6 Billion USD in 2018.
What is China Diabetes Devices Market size in 2028?
The China Diabetes Devices Market is valued at 8 Billion USD in 2028.
Who are the key players in China Diabetes Devices Market?
Abbott, Medtronics, Roche, Becton, Dickinson & Company, Dexcom are the major companies operating in China Diabetes Devices Market.
China Diabetes Devices Industry Report
Statistics for the 2023 China Diabetes Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. China Diabetes Devices analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.